Autonomous Blood Drawing Optimization and Performance Testing (ADOPT)

• ClinicalTrials.gov Identifier: NCT05878483
• Recruitment Status: Recruiting
• First Posted: May 26, 2023
• Last Update Posted: November 1, 2023
• Sponsor: Vitestro B.V.
• Information provided by (Responsible Party): Vitestro B.V.

Tracking Information

• First Submitted Date: May 17, 2023
• First Posted Date: May 26, 2023
• Last Update Posted Date: November 1, 2023
• Actual Study Start Date: July 21, 2023
• Estimated Primary Completion Date: July 2025 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: May 17, 2023)

First-time venipuncture success rate [ Time Frame: Baseline ]

Phase A/B1/B2/C1: Success is defined as blood flowing into blood tubes at first attempt; Failure is defined as no blood flowing in the blood tubes at all at first attempt. Phase C2: All blood tubes are filled sufficiently, no second venipuncture is required to obtain (all) the samples.

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: May 17, 2023)

• Rate of punctured participants [ Time Frame: Baseline ]
  The total number of participants that are punctured by the device is divided by the total number of included participants.
• Rate of hemolyzed samples [ Time Frame: Baseline ]
  All samples with an (automated) hemolysis-index of >0.5 hemoglobin g/l, are classified as hemolyzed. In the laboratories where reporting occurs in umol/l, 0.5 g/l is divided by a factor: 0.5 g/l / 1.6129= 31 umol/l.
• Adverse Events [ Time Frame: 7 days ]
  Number and type of Adverse Events (AE)s and Device Adverse Effects (ADEs) will be recorded and collected. A passive one week (7 days) follow-up occurs to determine whether any delayed adverse events occur.

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Autonomous Blood Drawing Optimization and Performance Testing
• Official Title: Autonomous Blood Drawing Optimization and Performance Testing

Brief Summary

The purpose of this pre-market clinical study is to evaluate the performance (efficacy) and safety of an autonomous blood drawing device (Venipuncture Device).

The study consists of several phases (A, B1, B2, C1, C2, 0).

Phase B1 is a confirmatory, Pivotal Clinical Study, required for regulatory approval, in which non-inferiority should be demonstrated in comparison to manual blood drawing.

Phases A, B2, C1, C2 are all exploratory studies, in which the technology and usability is further improved and tested. Phase 0 is an exploratory study for non-invasive technology testing (for example for improvement of ultrasound detection).

The study locations are outpatient blood drawing departments, in which patients are included as subjects. Additionally, in Phase A and C1, a small number of volunteers is included in a non-hospital site (Vitestro Site).

• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Not Applicable

Study Design

Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:

Anticipated number of participants distribution:

Phase A: 1,500 participants (max) Phase B1: 374 participants Phase B2/C1: 1,500 participants (max) Phase C2: 8,744 participants Phase 0: 1,500 participants (max)

The Phases are sequential, reflective of technology development:

Phase B1 should be completed before Phase B2/C1 can start. Phase B2 should be completed before Phase C2 can start.

Masking: None (Open Label)
Primary Purpose: Other

Condition

• Venipuncture
• Phlebotomy

Intervention

Device: Venipuncture Device (VD)

The Venipuncture Device is a pre-market medical device that fully automates the blood drawing procedure (also called phlebotomy or venipuncture). It automatically detects a vein using near-infrared and ultrasound imaging technology, robotically inserts a needle, automatically connects blood tubes and applies pressure to the puncture site.

During the ADOPT Study, the technology is further improved over time; for example features are released (such as: automated tourniquet). Initially, several manual steps are required to be performed by a device supervisor and operator. At the final stage of the ADOPT Study, Phase C2, the device has full functionality and only limited manual steps are required to be performed by a device supervisor.

Study Arms

Experimental: Autonomous blood drawing

Hospital Sites (outpatients visiting blood drawing department):

In study Phase A1, B1, B2, C1, a subject visiting the outpatient blood drawing department will receive one automated blood draw with the Venipuncture Device. This blood draw is additional to the manual blood draw.

In study Phase C2 the automated blood draw replaces the manual blood draw. In Phase C2, the subject might therefore receive two automated blood draws, in case a redraw is required.

Vitestro Site (volunteers):

In study Phase A, C1 volunteers visit Vitestro Site. Participants receive one to two automated blood draws.

Intervention: Device: Venipuncture Device (VD)

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: May 17, 2023): 13618
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: July 2025
• Estimated Primary Completion Date: July 2025 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Age ≥16 years.

Exclusion Criteria:

• Unable to follow instructions, due to mental disability and/or incapacity
• Unable to use device correctly due to physical impairment or disability (for example a patient with severe contractures or deformities)
• No venipuncture possible in cubital fossa of both arms (for example: after amputation of both arms)
• No venipuncture possible in cubital fossa due to contra-indications in both arms (for example: tattoos in both arms)
• Incapacitated persons
• Pregnant or breast-feeding

The following contra-indications / exclusion criteria are respected per arm:

• Arteriovenous fistula or vascular graft
• Paretic or paralyzed arm (e.g. after stroke or trauma)
• Infected skin in cubital fossa (for example: erysipelas or cellulitis)
• Mastectomy side, axillary lymph node excised
• Healed skin burns in cubital fossa
• Edema in cubital fossa
• Extensive scarring in cubital fossa
• Hematoma in cubital fossa
• Tattoos in cubital fossa

In case the test subject has a suitable contralateral arm, the subject can be included in this study. In Study Phase B2, a manual venipuncture and automated venipuncture are performed in both arms. Patients who have a contra-indication in one arm are excluded from the Phase B2 study.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 16 Years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Contacts

Contact: Luuk Giesen, MD; +31 30 200 45 51; luuk.giesen@vitestro.com

Contact: Jeroen Roest, MSc; +31 30 200 45 51; jeroen.roest@vitestro.com

• Listed Location Countries: Netherlands

Administrative Information

• NCT Number: NCT05878483
• Other Study ID Numbers: NL80965.000.22
• Has Data Monitoring Committee: No

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: Vitestro B.V.
• Original Responsible Party: Same as current
• Current Study Sponsor: Vitestro B.V.
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Principal Investigator: Luuk Giesen, MD; Vitestro B.V.

• PRS Account: Vitestro B.V.
• Verification Date: October 2023